ClinicalTrials.gg
RecruitingNCT07110129Updated Aug 21, 2025

Using sEMG of the Diaphragm to Assess Readiness for Extubation

An observational study in Critical Illness, sponsored by Cardiff and Vale University Health Board. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Cardiff and Vale University Health Board · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

As part of an admission to an Intensive Care Unit (ICU) many patients have breathing tube inserted into their windpipe, also referred to as intubation . This is done for a variety of reasons which can include the need for invasive breathing support and to place the patient into a medically induced coma to allow their body to rest and be treated for the underlying cause of their deterioration.

One the patient has started to recover from their illness, the process of removing the breathing tube (extubation) and stopping the breathing machine begins. Optimising this process and ensuring successful removal of the breathing tube is extremely important to optimise outcomes. Therefore, identifying new methods to determine the likelihood for successful extubation is of clinical significance.

There are several markers of extubation readiness that clinicians can use to support their decision making discussed in the literature. A novel method is the use of respiratory muscle activity monitoring via sensory electromyogram (sEMG). sEMG has previously been shown to be useful to measure the strength and activity of muscles. However, until recently measuring diaphragm activity has been a challenge due to noise from the chest movements, cardiac artefacts. Recent advancements in signal processing and growing interest in better diagnostic methods has led to an improvement in metrics. Using wavelet transforms and machine learning, new techniques have been developed to measure diaphragm muscle activity using sEMG. sEMG has been shown to be effective in detecting patient-ventilator asynchrony as well as respiratory strength in those not requiring mechanical ventilation. However, its use in assessing patients nearing readiness for extubation has not been explored.

Therefore, the purpose of this feasibility trial is to explore the use of sEMG in patients undergoing trials of extubation. The results of this study will be used to design a multi-site trial.

Read the detailed description

150,000 patients a year in the UK need to be admitted to a critical care unit. Those admitted are usually either critically unwell or are in the recovery phase of a critical illness (1). Often patients will require support for one or more of their vital organs such as their lungs, heart or kidneys. Approximately 60% of patients admitted will require support from mechanical ventilation (breathing machine) (2).

Mechanical ventilation is lifesaving when indicated but is beset by potential complications as the duration increases (3). Early identification of patients who are ready to be liberated from ventilatory support is therefore key. However, clinician judgement lacks both sensitivity and specificity for identifying such patients.

A Cochrane review in 2010 (4) demonstrated protocolised and standardised weaning method reduced the duration of total mechanical ventilation by 25%, weaning duration time by 78% and Intensive Care Unit (ICU) length of stay by 10%. Conversely, prolonged weaning process worsens patient outcomes, increases the risk of dying, and increases length of ICU and hospital stay, affects finite critical care resource and a direct impact on financial cost and environment sustainability (5).

Predicting readiness for extubation is challenging. This task is best accomplished by means of a protocolised process including a spontaneous awakening trial (SAT) where sedation is lowered to a safe RASS target and a spontaneous-breathing trials (SBT), in which patients who meet a defined set of criteria undergo a test period of minimal (Pressure support ventilation) or no ventilator (T-piece) support (6). This is then frequently combined with objective markers or 'extubation indices'. These indices include assessments of breathing strength and endurance, cough strength and respiratory distress e.g., P0.1, MIP, Peak cough flow and RSBI. However, these indices have been shown to lack sensitivity and specificity, with none of them able to accurately predict readiness for extubation or likely success (7).

The incidence of extubation failure reported in literature is quite variable with \~5% in post-operative surgical units to 10% in medical ICUs. With each additional day without a weaning success after the first attempt, there is an associated increase in crude mortality. Crude mortality increased from 19.0% in patients not weaned one day after the first attempt to 36.8% in patients still present in the ICU and not successfully weaned 10 days after the first attempt (8). Studies have also demonstrated that patients requiring reintubation are at increased risk of death with mortality rates ranging as high as 43% compared with less than 12% in patients successfully extubated (9). Reintubation is associated with a 4.5 times increased risk of nosocomial pneumonia (10).

Therefore, identifying new methods for determine likelihood for successful extubation is of clinical importance. Once such novel method is the use of respiratory muscle activity monitoring via sensory electromyogram (sEMG). sEMG has previously been shown to be useful to measure the strength and activity of muscles (11). However, until recently measuring diaphragm activity has been a challenge due to noise from the chest movements, cardiac artifacts. Recent advancements in signal processing and growing interest in better diagnostic methods has led to an improvement in metrics (12). Using wavelet transforms and machine learning, new techniques have been developed to measure diaphragm muscle activity using surface EMG electrodes placed at the 6-8th intercostal space along the mid-axillary or mid-clavicular line (13). Indeed, a pilot study looking at the sEMG of the diaphragm in healthy humans has shown that we are able to predict the inspiratory load of 6 participants with over 70% accuracy. sEMG has also been shown to be effective in detecting patient-ventilator asynchrony as well as respiratory strength in those not requiring mechanical ventilation (14). However, its use in assessing patients nearing readiness for extubation has not been explored.

Therefore, the purpose of this feasibility trial is to explore the use of sEMG in patients undergoing trials of extubation. The results of this study will be used to design a multi-site trial.

02

Conditions studied

  • Critical Illness

Browse trials for

03

In context

Critical Illness

1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.

This study's planned enrollment of 30 is below the median of 140 across 814 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Cardiff and Vale University Health Board is the lead sponsor of 44 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to critical care for level 3 support

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients requiring mechanical ventilation for >72 hours
  • Patients who an attempt at extubation is planned
  • Patients who are willing or able to give (Where consultee advice is sought, informed consent from the participant will be completed as soon as possible).

Exclusion criteria

Exclusion Criteria:

  • Aged under 18 years
  • Patients admitted with traumatic or spontaneous brain injury
  • Patients for who extubation is planned as a palliative process
  • to using sEMG e.g., permanent or temporary pacemaker, internal or external cardiac defibrillator, skin lesions around site of electrode placement
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Critical care cohort

    Critical care cohort - all to have EMG completed. No other intervention

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment and retention of participants

    To determine study feasibility by recruitment and retention rates from study participants across a single site

    Time frame: 1 year

Secondary outcomes

  1. Appropriateness of use of EMG for diaphragm strength

    To determine the appropriateness of sEMG in assessing diaphragm strength in relation to extubation

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110129
Lead sponsor
Cardiff and Vale University Health Board
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Aug 31, 2025 (estimated)
Primary completion
Jan 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Aug 21, 2025

Study contacts

Paul Twose, PhD
Contact
paul.twose@wales.nhs.uk
+447739315830

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion